A randomized, double-blind, placebo-controlled, Proof of Concept, study of 12 week treatment with RBx 10017609 in subjects with moderate to severe chronic obstructive pulmonary disease (COPD).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2016
At a glance
- Drugs RBx 10017609 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- 25 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by Clinical Trials Registry - India.
- 27 Mar 2012 New source identified and integrated (EudraCT2010-024640-15; European Clinical Trials Database).
- 04 Oct 2011 New trial record